Bactiguard Holding AB (publ.) has announced its updated strategic and financial targets following a review announced in connection with the 2024 Q3 report. The updated targets reflect a sharpened strategic focus on the license business and EBITDA profitability, a transformation delivered in 2024.
Bactiguard Holding AB (publ) published its year-end report for 2024 on Thursday 6 February 2025 at 07:00 CET.
Bactiguard hosted an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind presented the report and answer questions together with CFO Patrick Bach.
The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
To champion a healthier world by preventing infections.
To be the global standard of care for preventing medical device related infections.
To be the premier partner for leading MedTech companies, joining forces to redefine healthcare and improve health worldwide.
Bactiguard is a purpose-driven company with a strong corporate culture, firmly anchored in four core values. The values are an integral part of Bactiguard’s purpose to champion a healthier world by preventing infections and a prerequisite to achieve our targets.
The ambition is to become a profitable knowledge and specialist organization which is a prerequisite to deliver on our financial, strategic and sustainability targets.
Head of Corporate Communication & Investor Relations
+46 70 855 0356